David Hutton

Bausch + Lomb has agreed to acquire the Blink product line for $106.5 million.

Since 2014 when a sheet of retinal pigment epithelial cells derived from iPS cells was transplanted into patients with age-related macular degeneration, clinical trials have been conducted with various cell types derived from iPS cells.

In a study of 1.7 million older Americans by a team of researchers from the University of Toronto, those living in counties with an average temperature of 60°F or above had an increased chance of suffering serious vision impairment than those in cooler counties.

A study found the approach identifies high-risk patients so all preemies don’t need to undergo an invasive eye exam.

Surgeon discusses latest trends for treating cornea.

Clinical trial investigator Victor H. Gonzalez, MD, presented data at the 83rd Scientific Sessions of the American Diabetes Association in San Diego, California.

Orbis International physician spotlights the latest trends for cataract surgery training.

Special Superior Court Judge Mark A. Davis ruled that Michael Woodcock, MD’s failure to answer court filings did not mean he admitted his guilt in the allegations made by Cumberland County Hospital System.

According to Horizon Therapeutics, the analysis shows subclinical spinal cord lesions were associated with future NMOSD attacks. The analysis was being presented at the 9th Congress of the European Academy of Neurology in Budapest.

According to the companies, the divested assets will include Xiidra and SAF312, a potential therapy for chronic ocular surface pain. The deal is expected to close later this year.

In his role as president elect, SriniVas Sadda, MD, will continue to serve on the board as well as begin planning for his term as president, which will kick off next May at the conclusion of ARVO’s 2024 Annual Meeting in Seattle, Washington.

As part of its effort, the company is kicking off a new social media campaign in July designed to increase the understanding of dry eye disease.

According to Regeneron, visual gains and safety of aflibercept 8 mg remained consistent with the established profile of aflibercept 2 mg Injection.

A recently completed non-human primate study of VGX-0111 demonstrated good tolerability, provided strong transgene expression in the targeted region of the retina, and increased production of the lipids whose decline is associated with macular degeneration.

Data from IG-002, Intergalactic's lead program, demonstrate persistent ABCA4 expression in non-human primate retinas over six months after a single administration, and support plan to advance IG-002 into Phase 1 trials in 2024.

Sparklers and firecrackers are at the top of the list for fireworks-related injuries. The organization is advising the public to leave fireworks to licensed operators.

Maria Montero, MD, of Orbis sits down with David Hutton of Ophthalmology Times, to discuss technology and training for cataract surgery, including simulation, and telementoring.

According to the company, the study will identify hematology biomarkers that could personalize medical evaluations for patients undergoing treatments for macular degeneration.

A late breaking poster at the event in San Diego presented by Paolo S. Silva, MD, reveals AI algorithms for diabetic retinopathy progression risk estimation.

According to researchers, the new imaging approach reveals changes in retinal microcirculation may indicate brain diseases that involve reduced blood flow.

Kaushal Solanki, PhD, discusses how ophthalmologists can now use the Topcon NW400 retinal camera with its EyeArt AI system to automatically detect diabetic retinopathy.

According to researchers, the study is the first to assess associations between pre-diagnostic circulating metabolites and POAG risk in two large independent datasets.

The company noted the FDA clearance also includes its proprietary Real-Time Quality Feedback to improve the gradeability of retinal images and reduce the need for eye dilation, expanding the choice for primary care clinics to screen people with diabetes.

Cigna’s Coverage Policy includes procedures enabled with OMNI® Surgical System technology as medically necessary and covered.

Experts in the field weigh in on the perfluorohexyloctane ophthalmic solution, the first and only FDA-approved treatment for DED that directly targets tear evaporation instead of tear formation.

Patients with eye disease have an increased risk for developing neurodegenerative disease, and several studies have established a link between neurodegenerative diseases and ophthalmic conditions like glaucoma, diabetic retinopathy, age-related macular degeneration.

In a presentation at the American Society for Microbiology’s annual meeting, the oral administration of a commercially available probiotic bacterial strain was found to improve dry eye disease in an animal model.

AG-80208 is a novel, first-in-class, formyl peptide receptor (FPR) agonist formulated as an aqueous solution eye drop to treat the inflammation linked with DED.

In April, the FDA approved an update to the TEPEZZA indication language, specifying its use in all patients with TED regardless of TED activity or duration. Horizon Therapeutics presented its data at the Endocrine Society's 2023 annual meeting in Chicago.